Donna Roy Grogan
Known title: DirectorCIK: 0001788455
Associated companies
Transaction History
| CCCC | ▲ Buy | Grant | 4,618 | $15K | 10/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 3,341 | $14K | 7/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 5,370 | $14K | 4/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 7,513 | $15K | 1/2/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 6,740 | $14K | 10/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 9,609 | $15K | 7/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 9,581 | $14K | 4/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 3,757 | $14K | 1/2/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 2,474 | $14K | 10/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 2,836 | $14K | 7/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 1,697 | $14K | 4/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 2,108 | $14K | 1/2/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 8,089 | $14K | 10/2/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 4,858 | $14K | 7/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 4,298 | $14K | 4/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 1,763 | $11K | 1/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 819 | $7K | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.